Skip to the main content

What is Stand Up To Cancer?  Why are they important?

Here’s what you need to know about SU2C:

  • Since Stand Up To Cancer was founded in May 2008, the SU2C research portfolio has engaged more than 1,200 researchers from over 140 health and medical institutions who have planned, initiated or completed more than 170 clinical trials involving more than 9,000 patients.
  • In May 2009, SU2C launched its first 5 scientific Dream Teams. Today, 20 Dream Teams have been launched, driven by the same principles that laid the foundation of the Stand Up To Cancer model: collaboration, innovation, acceleration and translational research.
  • Unprecedented Dream Team Approach: SU2C’s revolutionary Dream Teams bring together top researchers from different institutions to work together on promising new approaches to fight cancer. Each Dream Team is composed of leading scientists working in collaboration to accelerate discovery and delivery of new and better therapies to patients across cancer types, bringing together basic biology, clinical oncology, technology and engineering. This unique funding model, called “revolutionary" by NIH Director Dr. Francis Collins, has realized SU2C’s promise to the public that SU2C would get new treatments from the bench of a scientist to the bedside of a patient in 3 years. “It is the best dollar spent in this country for support of cancer research and benefit of patients,” said Nobel Laureate Phillip A. Sharp, Ph.D.
  • Innovative Research Grants (IRGs): Stand Up To Cancer supports cutting edge cancer research by early-career scientists whose high risk, high-reward ideas have great potential to impact patient care. To date, 46 young investigators have received significant grants over a 3-year period.

Learn more at